Elekta hits bottom of STOXX after Q4 EBIT miss
** Shares in Elekta EKTAb.ST slump 14% to the bottom of Europe's STOXX 600 .STOXX after the Swedish radiation therapy equipment maker posted bigger-than-expected drop in Q4 profit
** Q4 adj. EBIT falls 22% to SEK 651 million ($62.5 million), missing consensus by 21% according to J.P.Morgan
** JPM ("underweight") points to a challenging market and launch costs for Elekta Evo as results for the miss
** Elekta's CEO says he is not satisfied with Q4 outcome and expects H1 of FY 2024/25 to be weaker as well due to challenging market conditions
** The stock is on track for its worst day since February 2019 if losses hold
($1 = 10.4162 Swedish crowns)
Reporting by Anna Chaberska
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
